NSCLC IO 2022 - Midyear Review

In real-world practice, the combination of immune checkpoint inhibitors with chemotherapy in patients with metastatic NSCLC may delay progression compared with immune checkpoint inhibitors alone but does not affect long-term outcomes. Read More ›

A noncoding single-nucleotide polymorphism in the CTLA-4 gene was found to be common among responders to anti–PD-1/PD-L1 therapies, which may enhance the clinical effect of PD-1 blockade. Read More ›

Mutations in the ATM gene, the most mutated DNA damage and repair gene in cancer, were found to define distinct subsets of patients with NSCLC with unique genomic characteristics, clinicopathologic features, and sensitivity to chemoimmunotherapy. Read More ›

Sugemalimab plus chemotherapy resulted in statistically significant and clinically meaningful progression-free survival and overall survival improvement compared with placebo plus chemotherapy, regardless of tumor histology or PD-L1 expression level, in patients with newly diagnosed metastatic NSCLC. Read More ›

First-line treatment of patients with advanced NSCLC with toripalimab plus chemotherapy resulted in improved progression-free survival and overall survival compared with chemotherapy alone. Read More ›

The combination of nivolumab plus docetaxel for NSCLC in the second-line setting improved overall survival, progression-free survival, and overall response rate, despite a slightly elevated risk of toxicity. Read More ›

The combination of canakinumab and pembrolizumab plus chemotherapy did not statistically improve efficacy as first-line treatment in patients with advanced NSCLC. Read More ›

Neoadjuvant treatment of patients with resectable early-stage NSCLC with durvalumab in combination with the anti-CD73 monoclonal antibody oleclumab, the anti-NKG2A monoclonal antibody monalizumab, or the anti-STAT3 antisense oligonucleotide danvatirsen resulted in improved efficacy compared with durvalumab alone. Read More ›

Neoadjuvant nivolumab plus platinum-doublet chemotherapy resulted in clinically meaningful improvement in event-free survival and pathologic complete response in patients with resectable NSCLC compared with chemotherapy alone. Read More ›

The 3-year extended follow-up of CheckMate 9LA demonstrated that first-line nivolumab plus ipilimumab in combination with limited chemotherapy resulted in long-term, durable clinical benefit compared with chemotherapy alone in patients with metastatic NSCLC, regardless of PD-L1 mutation status. Read More ›

Page 2 of 3

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications